内科

【摘要】目的观察瑞舒伐他汀钙治疗对冠心病（CHD）合并阵发性房颤（PAF）患者心功能及可溶性E选择素（sEselectin）、转化生长因子β1（TGFβ1）的影响。方法选取我院收治的CHD合并PAF患者124例作为研究对象，按照随机数字表法分为观察组和对照组各62例，其中对照组患者给予常规治疗，观察组患者在常规治疗的基础上给予瑞舒伐他汀钙治疗。比较两组患者的临床疗效、左心室舒张末内径（LVEDD）、左心室收缩末内径（LVESD）、左室射血分数（LVEF）和sEselectin、TGFβ1水平。结果观察组患者治疗总有效率（91.94%）显著高于对照组（77.42%），差异有统计学意义（P＜0.05）。治疗后，两组患者LVEDD、LVESD显著低于治疗前（P＜0.05），观察组患者显著低于对照组（P＜0.05）；两组患者LVEF显著高于治疗前（P＜0.05），观察组患者显著高于对照组（P＜0.05）；两组患者sEselectin水平显著低于治疗前（P＜0.05），观察组显著低于对照组（P＜0.05）；两组患者TGFβ1水平显著高于治疗前（P＜0.05），观察组显著高于对照组（P＜0.05）。结论在常规治疗的基础上，加用瑞舒伐他汀钙治疗能够有效改善CHD合并PAF患者sEselectin、TGFβ1水平和心功能，提高临床疗效。

【Abstract】ObjectiveTo explore the influence of rosuvastatin calcium on cardiac function and sEselectin, TGFβ1 in patients with coronary heart disease (CHD) complicated with paroxysmal atrial fibrillation (PAF). MethodsA total of 124 patients with CHD complicated with PAF in our hospital were divided into observation group and control group according to random number table method, with 62 cases in each group. The control group were given routine treatment, while the observation group received rosuvastatin calcium on the basis of routine treatment. Clinical effect, left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF) and the levels of sEselectin and TGFβ1 were compared between the two groups. ResultsThe total effective rate of the observation group (91.94%) was significantly higher than that of the control group (77.42%, P＜0.05). After treatment, LVEDD and LVESD in the two groups were significantly decreased compared with those before treatment(P＜0.05), and the decreased in the observation group was more significant(P＜0.05); LVEF in the two groups were significantly increased compared with those before treatment(P＜0.05), and the increased in the observation group was more significant(P＜0.05);the levels of TGFβ1 increased significantly while the levels of sEselectin decreased significantly in two groups after treatment in contrast with those before treatment (P＜0.01), and the levels of TGFβ1 in the observation group was significantly higher than that in the control group (P＜0.05), and the levels of sEselectin was significantly lower than that in the control group (P＜0.05). ConclusionsRoutine treatment combined with rosuvastatin calcium can effectively improve the level of sEselectin, TGFβ1 and cardiac function in patients with CHD complicated with PAF, and enhance clinical efficacy.